Zobrazeno 1 - 10
of 36
pro vyhledávání: ''
Autor:
Fernando Achinelli, Gerardo Andino, Maria Bangher, Paola Itati Reynoso, Antonia Cristina Aquino, Jorge Ojeda, Silvana Dellamea, Victor Flores, María Gabriela Aguirre, Elba Meza, Carolina N. Martemucci, Pablo Kawerin, Fabian Plano, Mariana Elizabeth Robledo, Claudia Campias, Hector Andres Guglielmone, Noelia Carolina Sosa, Evangelina Chaparro Campias, Rodrigo Zoni, Maria Mercedes Vernengo, Silvina Maria Martinez, Joaquina Maria Guarrochena, Natalia E. Ruiz Diaz, Diego Farizano Salazar, Julio Vallejos, Maria Fernanda Medina, Angelina Bobadilla, Silvina Villamandos, Juan Emanuel Segovia
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) has changed our lives. The scientific community has been investigating re-purposed treatments to prevent disease progression in coronavirus disease (COVID-19) patients. Objective
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-6 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Antibiotic-resistance reduces the efficacy of conventional triple therapy for Helicobacter Pylori infections worldwide, which necessitates using various treatment protocols. We used two protocols, doxycycline-based quadruple regimen and co
Publikováno v:
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-5 (2019)
BMC Infectious Diseases
BMC Infectious Diseases
Background Idiopathic CD4 lymphocytopenia (ICL) is a rare clinical disease with relative CD4 deficiency in the absence of HIV infection. The pathogenicity of ICL is poorly understood with an unclear incidence rate in the general population. Sequelae
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-11 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
Background Limited clinical studies describe the pharmacodynamics of fosfomycin (FOS), tigecycline (TGC) and colistin methanesulfonate (CMS) in combination against KPC-producing Klebsiella pneumoniae (KPC-Kp). Population pharmacokinetic models were u
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-10 (2021)
Abstract Background In people living with HIV (PLWH), statins may be disproportionately effective but remain underutilized. A large prospective trial in patients with low to moderate cardiovascular (ASCVD) risk will reveal whether they should be cons
Autor:
Tsan-Ming Huang, Kuan-Chih Kuo, Ya-Hui Wang, Cheng-Yi Wang, Chih-Cheng Lai, Hao-Chien Wang, Likwang Chen, Chong-Jen Yu, On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE)
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-8 (2020)
Objectives To investigate the incidence of active tuberculosis (TB) among COPD patients using fluticasone/salmeterol or budesonide/formoterol, and to identify any differences between these two groups of patients. Methods The study enrolled COPD patie
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-8 (2020)
BMC Infectious Diseases
BMC Infectious Diseases
BackgroundBK virus-associated nephropathy (BKVAN) is a relatively common cause of renal dysfunction in the first six months after renal transplantation. It arises from reactivation of the latent and usually harmless BK virus (BK virus) due to immunos
Autor:
Daniel Kiiza, Prosperity C. Eneh, Katherine Huppler Hullsiek, David B. Meya, David R. Boulware, Joshua Rhein, Melanie R. Nicol
Publikováno v:
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-11 (2020)
BMC INFECTIOUS DISEASES
BMC Infectious Diseases
BMC INFECTIOUS DISEASES
BMC Infectious Diseases
Background Management of co-infections including cryptococcal meningitis, tuberculosis and other opportunistic infections in persons living with HIV can lead to complex polypharmacotherapy and increased susceptibility to drug-drug interactions (DDIs)
Autor:
Sheri A. Lippman, Alyssa C. Mooney, Scott Barnhart, Jessica S Grignon, Hailey J. Gilmore, Teri Liegler, Gillian Hunt, Hong-Ha M. Truong, Lisa M. Prach, Adrian Puren
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Infectious Diseases, vol 20, iss 1
BMC infectious diseases, vol 20, iss 1
BMC Infectious Diseases, Vol 20, Iss 1, Pp 1-10 (2020)
BMC Infectious Diseases, vol 20, iss 1
BMC infectious diseases, vol 20, iss 1
Background Understanding factors driving virological failure, including the contribution of HIV drug resistance mutations (DRM), is critical to ensuring HIV treatment remains effective. We examine the contribution of drug resistance mutations for low
Autor:
Jean-Luc Berland, Phetsavanh Chanthavilay, Silaphet Somphavong, Phimpha Paboriboune, Thi Van Anh Nguyen, Sengaloun Soundala, Inthalaphone Keovichit, Anne-Laure Bañuls, Donekham Inthavong, Quang Huy Nguyen, Thi Thuong Vu, Phouvang Vongvichit, Vanthala Akkhavong, Gláucia Paranhos-Baccalà, Vibol Iem, Marie Gauthier
Publikováno v:
BMC Infectious Diseases
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-10 (2019)
BMC Infectious Diseases, Vol 19, Iss 1, Pp 1-10 (2019)
Background In Lao People’s Democratic Republic (PDR), tuberculosis (TB) prevalence was estimated at 540/100,000 in 2011. Nevertheless, little is known about the genetic characteristics and anti-TB drug resistance of the Mycobacterium tuberculosis p